Enliven Therapeutics ELVN Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's free cash flow yield?
- Enliven Therapeutics (ELVN) reported free cash flow yield of -2.8% in Q1 2026.
- How has Enliven Therapeutics's free cash flow yield changed year-over-year?
- Enliven Therapeutics's free cash flow yield increased by 63.5% year-over-year, from -7.7% to -2.8%.
- What is the long-term trend for Enliven Therapeutics's free cash flow yield?
- Over 5 years (2020 to 2025), Enliven Therapeutics's free cash flow yield has grown at a -4.4% compound annual growth rate (CAGR), from -9.7% to -7.7%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.